Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of cheno…
Biotechnology
US, San Diego [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Travere Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | -4.4300 | 3.050 | 28 | 98 | -110 | 226 | -74 | -66 | -79 | -73 | 59 | 92 |
| 2016 | 3.4900 | -1.323 | 99 | 132 | 117 | -98 | 129 | -88 | -32 | -98 | 79 | 123 |
| 2017 | -1.2900 | -1.255 | 133 | 154 | -47 | -93 | -38 | -103 | -39 | -114 | 98 | 144 |
| 2018 | -1.5400 | -1.833 | 154 | 164 | -59 | -136 | -38 | -110 | -30 | -122 | 103 | 154 |
| 2019 | -2.5400 | -2.836 | 164 | 174 | -102 | -210 | -73 | -116 | -68 | -129 | 103 | 163 |
| 2020 | -3.4600 | -1.446 | 175 | 198 | -146 | -107 | -107 | -133 | -99 | -147 | 128 | 186 |
| 2021 | -3.5600 | -3.012 | 198 | 225 | -169 | -142 | -143 | -103 | -75 | -128 | 135 | 122 |
| 2022 | -3.0100 | -4.476 | 227 | 208 | -180 | -176 | -186 | -133 | -139 | -159 | 149 | 144 |
| 2023 | -4.3700 | -1.618 | 212 | 195 | -278 | -376 | -299 | -146 | -251 | -175 | 220 | 159 |
| 2024 | -1.5000 | -3.923 | 145 | 229 | -111 | -293 | -326 | -190 | -388 | -207 | 265 | 226 |
| 2025 | - | -1.160 | - | 357 | - | -112 | - | -297 | - | -323 | - | 354 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |